Scott Holsten
Overview
Explore the profile of Scott Holsten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfano L, James M, Grosfjeld Petersen K, Rudolf K, Vissing J, Augsburger R, et al.
Ann Clin Transl Neurol
. 2024 Dec;
12(2):332-344.
PMID: 39675022
Objective: Limb-girdle muscular dystrophy R9 (LGMDR9, formerly known as LGMD2I), caused by variants in the fukutin-related protein (FKRP) gene leads to progressive muscle weakness of the shoulder and pelvic limb-girdles...
2.
Borland H, Moore U, Dressman H, Human A, Mayhew A, Hilsden H, et al.
Neuromuscul Disord
. 2024 Aug;
43:20-28.
PMID: 39178649
Dysferlin-deficient limb girdle muscular dystrophy (LGMD R2), also referred to as dysferlinopathy, can be associated with respiratory muscle weakness as the disease progresses. Clinical practice guidelines recommend biennial lung function...
3.
Reash N, James M, Alfano L, Mayhew A, Jacobs M, Iammarino M, et al.
Muscle Nerve
. 2022 May;
66(2):159-166.
PMID: 35506767
Introduction/aims: Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is...
4.
Mayhew A, James M, Moore U, Sutherland H, Jacobs M, Feng J, et al.
Front Neurol
. 2022 Apr;
13:828525.
PMID: 35359643
Dysferlinopathy is a muscular dystrophy with a highly variable functional disease progression in which the relationship of function to some patient reported outcome measures (PROMs) has not been previously reported....
5.
Jacobs M, James M, Lowes L, Alfano L, Eagle M, Lofra R, et al.
Ann Neurol
. 2021 Feb;
89(5):967-978.
PMID: 33576057
Objective: Dysferlinopathy is a muscular dystrophy with a highly variable clinical presentation and currently unpredictable progression. This variability and unpredictability presents difficulties for prognostication and clinical trial design. The Jain...
6.
Moore U, Jacobs M, James M, Mayhew A, Fernandez-Torron R, Feng J, et al.
Neurology
. 2019 Jan;
92(5):e461-e474.
PMID: 30626655
Objective: To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods: One hundred ninety-three patients with dysferlinopathy were recruited to...
7.
Sanjak M, Langford V, Holsten S, Rozario N, Patterson C, Bravver E, et al.
Arch Phys Med Rehabil
. 2017 May;
98(11):2301-2307.
PMID: 28465220
Objective: To determine the validity of the 6-minute walk test (6MWT) as an outcome measure to evaluate walking capacity in ambulatory patients with amyotrophic lateral sclerosis (ALS). Design: Observational study....
8.
Ward A, Hammond S, Holsten S, Bravver E, Brooks B
Assist Technol
. 2015 Dec;
27(4):238-45.
PMID: 26691564
The objectives of this study were to survey persons with Amyotrophic Lateral Sclerosis (ALS) at 1 and 6 months after receiving power wheelchairs to determine long-term use, comfort, and function...